•Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367048 | PMC |
| http://dx.doi.org/10.1016/j.ajpc.2024.100715 | DOI Listing |
Publication Analysis
Top Keywords
bempedoic acid
8
secondary prevention
8
cardiovascular outcomes
8
acid secondary
4
prevention •bempedoic
4
•bempedoic acid
4
acid reduce
4
reduce major
4
major adverse
4
adverse cardiovascular
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!